Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab.
Liu S, Yan S, Zhu J, Lu R, Kang C, Tang K, Zeng J, Ding M, Guo Z, Lai X, Jiang Y, Wu S, Zhou L, Sun L, Zhou ZW.
Liu S, et al. Among authors: sun l.
Int J Mol Sci. 2022 Aug 12;23(16):9014. doi: 10.3390/ijms23169014.
Int J Mol Sci. 2022.
PMID: 36012290
Free PMC article.